Review: Insufficient evidence exists to determine the benefits and risks of statins for acute ischemic stroke or TIA

Annals of Internal Medicine

Volumn 155, Issue 12, 2011, Pages

  Trowbridge, Robert L ^a  

^a MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN;

BLEEDING; BRAIN ISCHEMIA; COCHRANE LIBRARY; EMBASE; HUMAN; INFECTION; MEDLINE; MORTALITY; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE PATIENT; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 83755178535     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-155-12-201112200-02006     Document Type: Note

References (5)

1. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375: 1695-1703.
2. Gladstone DJ, Black SE, Hakim AM; Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002;33:2123-2136.
3. Goldstein LB. Statins and ischemic stroke severity: cytoprotection. Curr Atheroscler Rep. 2009;11:296-300.
4. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453-463.
5. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69: 904-910.